Nevro (NVRO) LT-Debt-to-Total-Asset : 0.37 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Nevro LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nevro's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.37.

Nevro's long-term debt to total assets ratio increased from Mar. 2023 (0.34) to Mar. 2024 (0.37). It may suggest that Nevro is progressively becoming more dependent on debt to grow their business.

Nevro LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nevro's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nevro LT-Debt-to-Total-Asset Chart

Nevro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.39

0.20

0.29

0.33

0.34

Nevro Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.34	0.34	0.35	0.34	0.37

Nevro LT-Debt-to-Total-Asset Calculation

Nevro's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	216.105	/	635.713
	=	0.34

Nevro's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	217.899	/	596.05
	=	0.37

Nevro (NYSE:NVRO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nevro LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nevro's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nevro (NVRO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nevro Corp (NYSE:NVRO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

1N7:Germany

Address

1800 Bridge Parkway, Redwood City, CA, USA, 94065

Website

https://www.nevro.com

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.

Executives

Greg Siller	officer: Chief Commercial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Shawn Mccormick	director	9600-54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55441
Kevin R Thornal	officer: President & CEO	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard B. Carter	officer: Chief Accounting Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Kashif Rashid	officer: General Counsel	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
D Keith Grossman	director, officer: President & CEO
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Michael F Demane	director, officer: Chief Executive Officer	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Niamh Louise Pellegrini	officer: Chief Commercial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Brad Vale	director	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Susan E Siegel	director	3000 SAND HILL ROAD, BLDG 3 STE 290, MENLO PARK CA 94025
Roderick H. Macleod	officer: Chief Financial Officer	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Patrick Schmitz	officer: Vice President, Operations	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065